4.5 Article

Management of Difficult-to-Treat Atopic Dermatitis

Journal

Publisher

ELSEVIER
DOI: 10.1016/j.jaip.2012.09.002

Keywords

Atopic dermatitis; Eczema; Review; Compliance; Corticosteroids; Tacrolimus; Cyclosporine

Funding

  1. Department of Defense
  2. Nutricia
  3. Abbott
  4. Astellas Inc
  5. Astellas
  6. Novartis
  7. Merck
  8. MEDA
  9. L'Oreal
  10. Pierre Fabre
  11. Janssen
  12. Hans Karrer
  13. ALK-Scherax
  14. Springer
  15. Thieme

Ask authors/readers for more resources

Atopic dermatitis is a complex disorder caused by the interplay between multiple genetic and environmental factors. Particularly in patients with severe disease, the effect is not just an itchy rash but also the secondary effects on the psychological well-being of the patient and their carers, particularly disturbed sleep. The aim of this review is to provide health care professionals with a holistic approach to the management of difficult-to-treat atopic dermatitis, defined as atopic dermatitis seemingly unresponsive to simple moisturizers and mild potency (classes VI and VII) topical corticosteroids. The critical importance of education and advice is emphasized, as is the seminal role of secondary bacterial infection and polyclonal T-cell activation in causing acute flares in patients with severe, generalized disease. In atypical cases or those that do not respond to treatment, alternative diagnoses should be considered. (C) 2012 American Academy of Allergy, Asthma & Immunology

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available